Read twice and referred to the Committee on Finance.
This bill (No Handouts for Drug Advertisements Act) amends the Internal Revenue Code to deny any tax deduction for expenses related to direct-to-consumer advertising of certain drugs. "Direct-to-consumer advertising" covers ads about covered drugs primarily targeted to the general public via broadcast, mail, billboards, internet, and digital platforms, but excludes journal and periodical publications. "Covered drugs" include prescription drug products and drugs compounded under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act; "covered entities" include sponsors of prescription drugs and owners of outsourcing facilities. The rule applies to amounts paid or incurred after enactment, for taxable years ending after that date.
Left trusts tax tool to curb pharma influence; right sees government overreach
Relative to its intended legislative type, this bill is a focused substantive amendment to the Internal Revenue Code that is concrete in mechanism and integration with existing law but limited in administrative, fiscal, and anti-avoidance detail.
This bill (No Handouts for Drug Advertisements Act) amends the Internal Revenue Code to deny any tax deduction for expenses related to direct-to-consumer advertising of certain drugs. "Direct-to-consumer advertising" covers ads about covered drugs primarily targeted to the general public via broadcast, mail, billboards, internet, and digital platforms, but excludes journal and periodical publications. "Covered drugs" include prescription drug products and drugs compounded under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act; "covered entities" include sponsors of prescription drugs and owners of outsourcing facilities.
The rule applies to amounts paid or incurred after enactment, for taxable years ending after that date.
Narrow but politically sensitive measure increases revenue yet provokes concentrated industry lobbying; lacks compromise features and clear bipartisan path.
Relative to its intended legislative type, this bill is a focused substantive amendment to the Internal Revenue Code that is concrete in mechanism and integration with existing law but limited in administrative, fiscal, and anti-avoidance detail.
Left trusts tax tool to curb pharma influence; right sees government overreach
These are examples from the analysis, not a ranked list of the most-affected groups.
Left trusts tax tool to curb pharma influence; right sees government overreach
Likely supportive because the bill removes a tax incentive for widespread pharmaceutical consumer marketing, seen as reducing industry influence.
They will view it as a market-based step to curb marketing-driven prescribing and potentially lower drug spending, while preferring stronger measures.
Cautiously mixed — sees a plausible public-interest rationale but worries about legal, fiscal, and practical tradeoffs.
Will weigh effectiveness, administrative complexity, and revenue impacts before supporting it.
Generally skeptical, viewing the bill as federal micromanagement and a tax penalty on lawful business activity.
Concerned it increases costs on drug companies and could reduce innovation or free-market information flows.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow but politically sensitive measure increases revenue yet provokes concentrated industry lobbying; lacks compromise features and clear bipartisan path.
The bill has not accumulated any surfaced votes yet.
Left trusts tax tool to curb pharma influence; right sees government overreach
Narrow but politically sensitive measure increases revenue yet provokes concentrated industry lobbying; lacks compromise features and clear…
Relative to its intended legislative type, this bill is a focused substantive amendment to the Internal Revenue Code that is concrete in mechanism and integration with existing law but limited in administrative, fiscal,…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.